Table 2.
Patient demographics stratified by clinical diagnosis of SpA.
SpA− (n = 26) | SpA+ (n = 54) | Overall a (n = 81) | |
---|---|---|---|
Age (mean [SD]) | 60 (8) | 47 (19) | 51 (17) |
Male (%) | 13 (50.0) | 19 (35.2) | 32 (39.5) |
Inflammatory back pain (%) | 9 (45.0) | 41 (87.2) | 51 (75.0) |
Enthesitis (heel) (%) | 1 (3.8) | 8 (15.4) | 9 (11.4) |
Arthritis (%) | 23 (88.5) | 44 (86.3) | 68 (87.2) |
Uveitis (%) | 2 (7.7) | 5 (9.4) | 7 (8.8) |
Dactylitis (%) | 1 (3.8) | 2 (3.8) | 3 (3.8) |
Psoriasis (%) | 9 (36.0) | 19 (36.5) | 28 (35.9) |
IBD (%) | 4 (15.4) | 4 (7.7) | 8 (10.1) |
Response to NSAIDs (%) | 11 (61.1) | 26 (74.3) | 37 (69.8) |
Family history of SpA (%) | 0 (0.0) | 4 (8.2) | 4 (5.3) |
Family history of psoriatic arthritis (%) | 3 (11.5) | 9 (18.4) | 12 (15.8) |
Family history of rheumatoid arthritis (%) | 2 (7.7) | 4 (8.2) | 6 (7.9) |
Family history of gout (%) | 1 (3.8) | 1 (2.0) | 2 (2.6) |
Family history of scleroderma (%) | 0 (0.0) | 1 (2.0) | 1 (1.3) |
Family history of ankylosing spondylitis (%) | 0 (0.0) | 3 (6.1) | 3 (3.9) |
Family history of IBD (%) | 1 (3.8) | 4 (8.2) | 6 (7.9) |
Elevated CRP or ESR (%) | 6 (26.1) | 11 (21.2) | 17 (22.4) |
HLA-B27 (%) | 1 (5.3) | 11 (22.9) | 12 (17.6) |
SpA spondyloarthritis, IBD inflammatory bowel disease, NSAIDs nonsteroidal anti-inflammatory drugs, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HLA human leukocyte antigen.
One case was indeterminate.